Background {#Sec1}
==========

Cholangiocarcinoma is the second most prevalent primary liver tumor worldwide, and its 3-year survival rate ranges from 20% to 60% in different regions due to difficulties in its diagnosis and poor responses to current therapies \[[@CR1]--[@CR5]\]. Surgical resection is the only feasible treatment modality that has a curative outcome for patients. Despite fast-paced improvements in surgical technique and experience, there is still a risk of massive blood loss and a subsequent need for blood transfusion. Blood transfusion is a double-edged clinical weapon that maintains blood volume to control hemorrhagic shock, supplies blood components to improve oxygen carrying capacity of blood, and regulates hemostasis by increasing blood coagulation factors. However, transfusions may cause short or severe complications including allergic reactions, hemolytic reactions, and immunosuppression. Several recent studies found PBT may be associated with worse postoperative outcomes for cancer patients \[[@CR6]--[@CR8]\]. However, without random controlled trials, it was debated whether systemic and statistic bias existed that led to this unreliable sign. Indeed, some reports argued that PBT has no impact on tumor recurrence and long-term mortality \[[@CR9]--[@CR12]\]. In this study, we summarize more than a decade of data at our institute and implemented a propensity score matching system to investigate the association between PBT and long-term outcome in ICC patients.

Methods {#Sec2}
=======

Participants and criteria {#Sec3}
-------------------------

The study enrolled 758 consecutive ICC patients who underwent curative surgery between 2000 and 2012 at the Liver Cancer Institute, Zhongshan Hospital, Fudan University. All resections were performed or supervised by experienced hepatobiliary surgeons and used standardized procedures \[[@CR13]\]. Additionally, all surgical specimens were confirmed by pathologic histology \[[@CR2]\]. The following exclusion criteria were used: pre-interventional therapy before liver surgery (*n* = 35, 27 underwent transcatheter arterial chemoembolization (TACE), 1 underwent radiofrequency ablation(RFA), 2 underwent radiotherapy, and 5 underwent RFA plus TACE); hemoglobin less than 70 g/L (*n* = 1); widespread metastasis (*n* = 4); TNM staging IVb (*n* = 89); missing data of hemoglobin before surgery (*n* = 14); missing data of blood transfusion (*n* = 5); and clinical source loss (n = 5) (Fig. [1](#Fig1){ref-type="fig"}). The eligible 605 patients included 93 cases who received perioperative allogeneic blood transfusion and 512 cases without transfusion. We defined the perioperative period as the time between the third preoperative day and the seventh postoperative day.Fig. 1Study flow chart

Data source {#Sec4}
-----------

All data on the patients' demographics, morbidity, postoperative mortality, and histological results were obtained from the hospital medical system. The TNM classification was based on the AJCC Cancer Staging Manual, Seventh edition (2010) by springer New York, Inc. All patients were followed-up regularly at outpatient clinics and the Liver Cancer Institute, Zhongshan Hospital, Fudan University. The follow-up results were obtained via telephone by an experienced researcher working in the Liver Cancer Institute. All patients were regularly followed in the outpatient department and tumor markers were measured every 3 months during the first 3 years and thereafter every 6 months until the study end or loss of follow-up. An abdominal ultrasound was performed every 3 months, and abdominal computed tomography or MRI was performed 6 months postoperatively or upon suspected recurrence. The median follow-up time was 20 months (range 0--134 months), and the end follow-up time was November 2015. The primary research endpoint was the death of patient or the end follow-up time, and the secondary endpoint was follow-up dropout. The OS was defined as the period from surgery until death due to any cause. DFS was defined as the duration from surgery until the date of intrahepatic cholangiocarcinoma recurrence. The transfusion of any blood visible components including red blood cells and blood plasma were considered blood transfusion. Blood management, including processing, testing, and transporting, were quality controlled by Shanghai Blood Center. The ABO and Rh status as well as blood cross matching were conducted by the blood department of Zhongshan hospital \[[@CR14]\].

Variables and statistics {#Sec5}
------------------------

The categorical variables are shown as whole numbers and proportions, and the continuous variables are described as the means with standard deviation as appropriate. Two-sided *p* values of \<0.05 were considered statistically significant. Statistical analyses were performed using IBM SPSS Statistics 22 and R statistical software. To compare continuous variables that followed Gaussian distributions, t tests were used; the K-Independent-Samples Test (Kruskal Wallis H(K) test) was used for those variables did not follow Gaussian distributions. To compare proportional variables, a Two-Independent-Samples Test (Mann-Whitney U test) was used, and a Two-Related-Samples Test (Wilcoxon Signed Ranks Test) was applied to matched propensity scores \[[@CR15]\]; all missing data are reflected in the available data \[[@CR16]\]. We examined the following parameters: age, gender, preoperative hemoglobin (Hb), platelets (PLT), aspartate aminotransferase (AST), alanine transaminase (ALT), alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen 19--9 (CA19--9), prothrombin time (PT), international normalized ratio (INR), hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (Anti-HCV), tumor maximum dimension (TMD), tumor node metastasis (TNM), intraoperative blood loss (IBL), degree of differentiation (DD), and transcatheter arterial chemoembolization (TACE). The confounders were measured accurately using univariate Cox regression through an enter variable selection procedure. The full variable selection logistic regression was used to specify a mathematical relationship for the variables related to blood transfusion \[[@CR17]\]. The regression models were based on Akaike's information criterion. We then adjusted for further confounding parameters in the propensity score analysis. This is a useful technique that focuses on the relationship between confounders and the treatment \[[@CR18], [@CR19]\]. The "PS MATCHING 3.03" and "SPSS Statistics R Essentials 22.0" and "R-2.15.3-win" R packages \[[@CR20]\] were used to perform the matching propensity score analysis. The matching confounders was estimated by the regression models described above, and balance matching showed the values of absolute standard mean difference (SMD). The demographics and characteristics of the matched patients were compared to ensure that there were no significant differences in the baseline settings. We used univariate and multivariate Cox regressions to assess the prognostic value of blood transfusion through balanced data. The GraphPad Prism 6 software was used to draw the survival curves depicting OS and DFS.

Results {#Sec6}
=======

Demographics and clinical characteristics of the 605 eligible patients before PSM {#Sec7}
---------------------------------------------------------------------------------

Of these patients, 93 (15.37%) received blood transfusion, and 512 (84.63%) did not. We described the patient demographics and clinical characteristics for the two groups separately (Table [1](#Tab1){ref-type="table"}). The clinical data for 9 of the 21 variables differed significantly (*P* \< 0.05) as a result of a conspicuous bias with pre-described PS (0.096 ± 0.104 vs. 0.479 ± 0.372 *P* \< 0.001).Table 1Demographics and clinical characteristics of 605 eligible patients before PSMCharacteristicVariableBefore PSMNo-PBTPBT*P* value(*n* = 512)(*n* = 93)AgeY ± SD57.42 ± 10.81556.54 ± 11.8010.176^a^Genderfemale/ male190/32248/450.008^c^Preoperative Hbg/L ± SD132.53 ± 16.22118.63 ± 17.680.329^a^Platelet1 × 10^9^/L ± SD179.25 ± 64.02201.30 ± 97.350.038^a^Total bilirubinavailable data510(99.61%)92 (98.92%)umol /L ± SD24.98 ± 55.3586.79 ± 134.47\<0.001^b^ASTavailable data502(98.05%)90 (96.77%)U/L ± SD44.56 ± 87.0956.21 ± 57.45\<0.001^b^ALTavailable data509 (99.41%)92 (98.92%)U/L ± SD50.40 ± 95.2257.90 ± 67.280.002^b^AFPavailable data497 (97.07%)91 (97.85%)ng/mL ± SD95.28 ± 953.7293.02 ± 585.950.982^b^CEAavailable data489 (95.51%)87 (93.55%)ng/mL ± SD22.42 ± 154.0761.84 ± 330.140.060^b^CA19--9available data486 (94.92%)86 (92.47%)U/mL ± SD1152.16 ± 3116.142698.09 ± 4923.75\<0.001^b^PTavailable data506 (98.83%)91 (97.85%)s ± SD11.20 ± 9.2311.87 ± 3.110.093^b^INRavailable data502 (98.05%)89 (95.70%)Value ±SD0.98 ± 0.110.98 ± 0.140.910^b^HBsAgavailable data506 (98.83%)93 (100.00%)(−)/(+)302/20471/220.002^c^Anti-HCVavailable data502 (98.05%)93 (100.00%)(−)/(+)493/991/20.814^c^Tumor numberavailable data511 (99.80%)92 (98.92%)1/\>1426/8581/110.259^c^TMDavailable data509 (99.41%)93 (100.00%)cm6.48 ± 3.166.92 ± 3.440.284^b^TNM stageavailable data489 (95.51%)74 (79.57%)I/II/III/IVa294/80/17/9847/15/0/120.433^c^Cirrhotic noduleavailable data512 (100.00%)91 (97.85%)no/ yes344/16870/210.065^c^DDavailable data412 (80.47%)76 (81.72%)I/II-III/IV2/408/2 (0.49%)0/76/0 (0.00%)1.000^c^IBLavailable data503 (98.24%)93 (100.00%)\<1 L/≥1 L499/4 (99.20%)61/32 (65.59%)\<0.001^c^Preventive TACEno/yes474/38 (92.58%)86/7 (92.47%)0.972^c^Propensity Scoreavailable data501 (84.49%)92 (15.51%)0.096 ± 0.1040.479 ± 0.372\<0.001^ba^t test^b^K-Independent-Samples Test (Kruskal Wallis H(K) test)^c^Two-Independent-Samples Test (Mann-Whitney U test)Values are presented as n (%) or mean ± standard deviation(SD)Hb: hemoglobin; AST: aspartate aminotransferase; ALT: alanine transaminase; AFP: alpha fetoprotein; CEA: carcinoembryonic antigen; CA19--9: carbohydrate antigen 19--9; PT: prothrombin time; INR: international normalized ratio; HBsAg: hepatitis B surface antigen; Anti-HCV: anti-hepatitis C virus; TMD: tumor maximum dimension; TNM: tumor node metastasis; IBL: intraoperative blood loss; DD: The degree of differentiation;TACE: transcatheter arterial chemoembolization. PSM: propensity score matching; No-PBT: no-perioperative transfusion; PBT: perioperative transfusion

Confounding factors between the PBT groups and outcome {#Sec8}
------------------------------------------------------

To investigate whether the existing confounders led to any bias, a univariate Cox regression was conducted to filter out the 8 variables that were associated with the outcome without considering treatment. In the OS Cox regression model, the preoperative Hb, total bilirubin, ALT, CA19--9, anti-HCV, TMD, TNM stage, intraoperative blood loss variables were selected as independent prognostics for ICC patients. In the DFS Cox regression model, CEA, which was an extended prognostic, was picked out. Then, a univariate logistic regression was performed between patients who received blood transfusion and those who did not; the gender, preoperative Hb, PLT, total bilirubin, CA19--9, HBsAg, and intraoperative blood loss differed significantly. After multivariate analysis, only the preoperative Hb, total bilirubin, and intraoperative blood loss were left and were thus considered confounders that had to be adjusted to synthesize all of the regression models (Table [2](#Tab2){ref-type="table"}).Table 2A univariate Cox regression and a variable selection logistic regression for confounding factors based on Transfusion and No-transfusionCharacteristicVariablesBefore PSMUnivariate (OS, COX Regression)Univariate (DFS, COX Regression)Univariate (Logistic Regression)Multivariate (Logistic Regression)HR (95% CI)*P* value^a^HR (95% CI)*P* value^a^OR (95% CI)*P* value^a^OR (95% CI)*P* value^a^AgeY ± SD1.007 (0.998--1.017)0.1311.006 (0.997--1.014)0.2190.993 (0.973--1.013)0.477Genderfemalereference0.121reference0.145reference0.009reference0.506male1.184 (0.956--1.466)1.163 (0.949--1.425)0.553 (0.355--0.863)0.790 (0.393--1.585)Preoperative Hbg/L ± SD0.988 (0.981--0.994)\<0.0010.990 (0.985--0.996)0.0010.951 (0.937--0.965)\<0.0010.947 (0.927--0.967)\<0.001Platelet1 × 10^9^/L ± SD1.001 (1.000--1.003)0.1771.001 (0.999--1.002)0.2221.004 (1.001--1.007)0.0061.001 (0.997--1.006)0.537Total bilirubinumol/L + SD1.003 (1.002--1.004)\<0.0011.002(1.001--1.003)0.0011.007 (1.005--1.010)\<0.0011.006 (1.003--1.009)\<0.001ASTU/L ± SD1.000 (0.999--1.002)0.4871.001 (1.000--1.002)0.2051.001 (0.999--1.003)0.24ALTU/L ± SD1.001 (1.000--1.002)0.0291.001 (1.000--1.002)0.0491.001 (0.999--1.003)0.472AFPng/mL ± SD1.000 (1.000--1.000)0.3791.000 (1.000--1.000)0.4511.000 (1.000--1.000)0.983CEAng/mL ± SD1.000 (1.000--1.000)0.7451.001 (1.000--1.001)0.011.001 (1.000--1.002)0.108CA19--9U/mL ± SD1.000 (1.000--1.000)\<0.0011.000 (1.000--1.000)\<0.0011.000 (1.000--1.000)\<0.0011.000 (1.000--1.000)0.903PTs ± SD1.000 (0.988--1.012)0.991.008 (0.994--1.022)0.281.007 (0.986--1.028)0.507INRValue ±SD2.307 (0.949--5.605)0.0651.692 (0.742--3.855)0.2110.714 (0.095--5.388)0.744HBsAg(−)reference0.401reference0.232reference0.003reference0.126(+)0.912 (0.737--1.130)0.882 (0.718--1.084)0.459 (0.275--0.764)0.552 (0.258--1.183)Anti-HCV(−)reference0.04reference0.076reference0.814(+)0.395 (0.163--0.956)0.507 (0.240--1.073)1.204 (0.256--5.663)Tumor number1reference0.446reference0.559reference0.261\>11.122 (0.835--1.507)1.088 (0.821--1.441)0.681 (0.348--1.332)TMDcm1.052 (1.017--1.087)0.0031.057 (1.025--1.090)\<0.0011.041 (0.975--1.113)0.229TNM stageIreference\<0.001reference0.001reference0.784II1.105 (0.804--1.518)1.192 (0.882--1.611)1.173 (0.624--2.206)III2.167 (1.104--4.255)1.823 (0.961--3.455)0.000(0.000-.)IVa2.088 (1.592--2.739)1.657 (1.273--2.157)0.766 (0.390--1.503)Cirrhotic nodulenoreference0.274reference0.799reference0.067yes1.127 (0.910--1.397)1.028 (0.834--1.266)0.614 (0.365--1.035)DDIreference0.982reference0.997reference1.000II-III2997.401 (0.000-.)8142.694 (0.000-.)300,921,742.177 (0.000-.)IV2632.881 (0.000-.)8450.077 (0.000-.)1.000 (0.000-.)IBL\<1000 mLreference0.005reference0.002reference\<0.001reference\<0.001≥1000 mL1.733 (1.184--2.535)1.816 (1.243--2.652)65.443 (22.383--191.341)168.205 (43.249--654.184)Preventive TACEnoreference0.349reference0.144reference0.972yes0.841 (0.585--1.209)1.300 (0.914--1.848)1.015 (0.439--2.348)OS: overall survival; DFS: disease-free survival; OR: odd ratio; HR: hazard ratio; ".": indicate the exceeded value^a^likelihood ratio test

Demographics and clinical characteristics of 215 matched patients after PSM {#Sec9}
---------------------------------------------------------------------------

Before performing propensity score matching analysis, we used a calculation called "PS Power and Sample Size Calculations(Version 3.0, January 2009)" \[[@CR21], [@CR22]\] to estimate the ideal sample size. We are planning a study with 1 PBT subject matched to 4 no-PBT subjects, an accrual interval of 1 month, and additional follow-up after the accrual interval of 133 months. Prior data indicate that the median survival time on the no-PBT is 26 months. If the true median survival times on the PBT and no-PBT are 26 and 12 months, respectively, we will need to study 31 PBT subjects and 124 no-PBT subjects to be able to reject the null hypothesis that the experimental and control survival curves are equal with probability (power) 0.9(*β* = 0.1). The Type I error probability associated with this test of this null hypothesis is 0.01(*α*).

The propensity score matching procedure was performed to reduce confounding variables based on the three identified factors. The caliper was set at 0.05, and we used an optimal match ratio of 1:4. We found 52 of the 93 transfused patients were matched with 163 of the 512 no-transfused patients, which is more than the ideal sample size we calculated previously to obtain the significant conclusion. The propensity score suggests there were no biases in the matched groups (0.136 ± 0.117 vs. 0.193 ± 0.167, *P* = 0.785). Figure [2](#Fig2){ref-type="fig"} shows the matched data absolute standardized mean difference (SMD), and the SMD of all three confounders and PS decreased to less than 0.2. In Table [3](#Tab3){ref-type="table"}, the matched patient characteristics were compared, and no significant differences were shown between the groups, considering all 21 variables.Fig. 2The model values of absolute standard mean difference(SMD) before and after PSM. The SMD of propensity score and three confounders (Preoperative Hb, Total bilirubin, intraoperative blood loss) was depicted in all data round dot. The SMD of matched data was depicted in squared dot Table 3Demographics and clinical characteristics of 215 patients after PSMCharacteristicVariableAfter PSMNo-PBTPBT*P* value(*n* = 163)(*n* = 52)AgeY ± SD57.67 ± 10.7756.90 ± 12.340.114^a^Genderfemale/male72/9127/250.330^c^Preoperative Hbg/L ± SD125.38 ± 15.90120.25 ± 18.720.232^a^Platelet1 × 10^9^/L ± SD180.29 ± 65.50193.38 ± 93.350.350^a^Total bilirubinumol/L ± SD31.34 ± 62.7760.36 ± 115.370.070^b^ASTavailable data161 (98.77%)50 (96.15%)U/L ± SD46.25 ± 81.7447.92 ± 62.240.763^b^ALTU/L ± SD51.14 ± 80.6453.35 ± 77.740.374^b^AFPavailable data158 (96.93%)52 (100.00%)ng/mL ± SD196.77 ± 1590.50123.49 ± 741.510.994^b^CEAavailable data157 (96.32%)49 (94.23%)ng/mL ± SD22.66 ± 149.8195.03 ± 437.780.375^b^CA19--9available data156 (95.71%)48 (92.31%)U/mL ± SD1170.62 ± 3041.711491.47 ± 3691.90.439^b^PTavailable data161 (98.77%)51 (98.08%)s ± SD10.76 ± 4.6511.96 ± 3.590.075^b^INRavailable data158 (96.93%)50 (96.15%)Value ±SD0.98 ± 0.130.98 ± 0.150.997^b^HBsAgavailable data160 (98.16%)52 (100.00%)(−)/(+)100/6039/130.100^c^Anti-HCVavailable data159 (97.55%)52 (100.00%)(−)/(+)157/251/10.726^c^Tumor number1/\>1140/2343/90.574^c^TMDcm6.84 ± 3.396.83 ± 3.380.967^c^TNM stageavailable data155(95.09%)44 (84.62%)I/II/III/IVa92/24/5/3425/11/0/80.968^c^Cirrhotic noduleavailable data163 (100%)50 (96.2%)no/yes112/5140/100.123^c^DDavailable data126 (77.30%)43 (82.70%)I/ II-III2/124 (1.59%)0/43 (0.00%)0.407^c^IBL\<1 L/≥1 L161/2 (98.77%)52/0 (100.00%)0.423^c^Preventive TACEno/yes153/10 (93.87%)47/5 (90.38%)0.392^c^Propensity Score0.136 ± 0.1170.193 ± 0.1670.785^da^t test^b^K-Independent-Samples Test (Kruskal Wallis H(K) test)^c^Two-Independent-Samples Test (Mann-Whitney U test)^d^Two-Related-Samples Test (Wilcoxon Signed Ranks Test)Values are presented as n (%) or mean ± standard deviation

Perioperative blood transfusion has no effect on OS and DFS after PSM {#Sec10}
---------------------------------------------------------------------

The univariate Cox proportional hazards regression analysis indicated PBT has a poor effect on OS and DFS before propensity score matching, which forebodes an 88.9% risk of overall mortality (HR: 1.889, 95% CI: 1.446--2.468, *p* \< 0.001) and 58.9% risk of DFS (HR: 1.589, 95% CI: 1.221--2.067, *p* \< 0.001). Additionally, the Kaplan-Meier curve of OS showed the no-transfused group has a significant benefit compared with transfused group (*p* \< 0.0001) (Fig. [3](#Fig3){ref-type="fig"}), the median survival months(MSMs) of PBT (12 months) is obviously less than non-PBT (26 months), Of note, no difference was found in DFS (*p* = 0.3807), same as the MSMs (PBT = 15 months, non-PBT = 16 months). However, after performing a multivariate risk dependent Cox regression we found that neither OS (HR: 1.172, 95% CI: 0.756--1.816, *p* = 0.479) nor DFS (HR: 0.944, 95% CI: 0.608--1.466, *p* = 0.799) was significantly different due to blood transfusion. Our findings suggest it was not a statistically independent prognostic risk. After propensity score matching, PBT had no significant effect on the risk of OS (HR: 1.429, 95% CI: 0.972--2.103, *p* = 0.070) and DFS (HR: 1.262, 95% CI: 0.858--1.856, *p* = 0.238) (Table [4](#Tab4){ref-type="table"}). Furthermore, the Kaplan-Meier plot showed similar trends for OS (*P* \< 1.000) and DFS (*P* \< 0.230). Both PBT and non-PBT MSMs to OS is 21 months and no significant difference (PBT = 12 months, non-PBT = 15 months) to DFS.Fig. 3Kaplan-Meier survival plot of OS and DFS before and after PSM. The survival curve of overall survival and disease-free survival in unadjusted model (**a**, **b**). The survival curve of overall survival and disease-free survival after matched (**c**, **d**). Median survival months were showed in each figure Table 4Univariate and multivariate Cox analysis predicting OS and DFS based on Transfusion and No-transfusionCharacteristicVariableBefore PSMAfter PSMunivariatemultivariateunivariateHR (95% CI)*P* value^a^HR (95% CI)*P* value^a^HR (95% CI)*P* value^a^PBT(OS)noreference\<0.001reference0.479reference0.070yes1.889 (1.446--2.468)1.172 (0.756--1.816)1.429 (0.972--2.103)PBT(DFS)noreference0.001reference0.799reference0.238yes1.589 (1.221--2.067)0.944 (0.608--1.466)1.262 (0.858--1.856)^a^likelihood ratio test

Discussion {#Sec11}
==========

Several studies have focused on how PBT affects gastrointestinal carcinomas and other tumors \[[@CR6]--[@CR8], [@CR10], [@CR11], [@CR14], [@CR23], [@CR24]\], and some concluded that PBT led to a poor outcome and increased the probability of recurrence \[[@CR6]--[@CR8], [@CR25], [@CR26]\]\]. However, others reported that PBT was not an independent prognostic factor for tumor recurrence and OS \[[@CR24]\]. Müller et al. reached the same conclusion in a study of 128 advanced cholangiocarcinoma patients \[[@CR9]\]: the small number of sources and heterogeneity from a mixture of intrahepatic, hilar, and distal cholangiocarcinoma may result an unconvincing selection bias. In our consecutive retrospective cohort study with 758 patients, we only recruited those who had intrahepatic cholangiocarcinoma without metastasis, and we found that PBT had no prognosis-related effect on OS and DFS.

We first explored the variables in 605 patients and found a significant bias between the two groups, which is consistent with previous reports. The survival analysis showed transfusion was an independent prognostic cause of OS and DFS. Moreover, we tried to determine which variables interacted with the outcome and treatment, using a combination of logistic and Cox regressions, and we found three interference factors: preoperative Hb, total bilirubin, and intraoperative blood loss. The propensity score matching was performed to reduce the confounding influence based on the three factors. To obtain the optimal matching data, the match ratio of 1:4 and a general caliper value of 0.05 were applied based on Abadie's research \[[@CR17]\]. We matched 52 transfused patients to 163 no-transfused patients, and all SMD values were less than 0.2, which suggests that the matching model was well adjusted \[[@CR27]\]. A further exploration of all variables was performed using the same statistical method, and no significant bias persisted between the groups in terms of the *P* value and PS. The survival analysis of OS and DFS also revealed that PBT had no effect on OS or DFS. Admittedly, we could not deny its effect on delaying the duration of the hospital stay, a higher probability of complication such as febrile reaction, allergic reaction, graft-vs. -host disease (GVHD), hemolytic reaction, and other long-term results like virus infection and immunosuppression.

Fundamental confounding factors and inappropriate statistical methods may result in the illusion that PBT may lead to poor survival. Lian X et al. demonstrated the positive viewpoint by using a large gastric adenocarcinoma data set \[[@CR6]\]. They revealed that PBT resulted in poor prognosis but not an independent prognostic factor based on a univariate and multivariate Cox analysis. The explanation might be different distribution of clinicopathological features between two groups and some confounder existed, such as TNM stage and intraoperative blood loss. Our ICC data set indeed found that intraoperative blood loss is an important confounder, in fact, it is more likely to transfuse blood for those massively bleeding patients. Norihisa Kimura et al. concluded that PBT was a strong risk factor for both recurrence and poor survival based on 66 HCCA after aggressive surgical resection \[[@CR8]\], they also kindly pointed out their limit of the small sample size may have resulted in a loss of statistical power. Finding that such confounders could adversely cover up the truth. Therefore, an appropriate technique such as PSM must be performed to avoid the bias before the final analysis, and ideal sample size of matched pairs may be necessary to strength the conclusion.

There are several limitations in this study. First, although the propensity score matching analysis is an acceptable method of simulating a random controlled trial, but it is still not sufficient to make up for the value of RCTs in circumstances with ethical challenges. Second, our study only recruited patients within China, and the results may not be applicable to other countries especially western states. Third, the exclusion of patients in the propensity score matching analysis reduced the statistical power. Finally, unknown or unobserved confounding factors may contribute to potential bias because the missing source collection and available data may result in information bias.

Conclusions {#Sec12}
===========

In conclusion, our data suggest that PBT was not associated with the long-term outcome of ICC. Inappropriate statistical analyses may lead to variable results, and risk adjustments can eliminate the detrimental effect.
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